image credit: Unsplash

Antibody-Drug Combination Regresses Pancreatic Tumor in Mice

According to the National Cancer Institute, about 10% of patients with pancreatic cancer (PC) remain alive five years after diagnosis. Tumor size has a strong impact on survival rates. The larger the tumor, the less likely it is to be cured by resection. There have been cases, however, where large tumors have been removed by surgery—and now there may be added hope. A preclinical study from the lab of Marsha Moses, PhD, at Boston Children’s Hospital, reports marked and lasting tumor regression in a mouse model, using a highly selective, engineered antibody-drug combination.

Read More on Genetic Engineering and Biotechnology News